News and press releases - Cantargia

* (R) = Regulatory press releases

06 Sep, 2021

(R) Cantargia expands nadunolimab development in non-squamous NSCLC

01 Sep, 2021

(R) Cantargia strengthens the company management team

30 Aug, 2021

(R) Cantargia reports preclinical data highlighting advantages of nadunolimab mechanism of action

26 Aug, 2021

(R) Cantargia reports first patient treated in CAPAFOUR study investigating combination of nadunolimab with FOLFIRINOX in pancreatic cancer

19 Aug, 2021

(R) Cantargia expands CIRIFOUR trial after successful completion of recruitment in the pembrolizumab combination arm

19 Aug, 2021

(R) Cantargia publishes half year report

10 Aug, 2021

Invitation to presentation of Cantargia’s report for the second quarter of 2021 on August 19 at 3.00 p.m. CET

01 Jul, 2021

(R) Cantargia advances development of nadunolimab in triple negative breast cancer through submission of clinical protocol for TRIFOUR study

01 Jul, 2021

(R) Cantargia advances development of nadunolimab in triple negative breast cancer through submission of clinical protocol for TRIFOUR study

29 Jun, 2021

(R) Cantargia broadens the development of nadunolimab in three forms of cancer and submits application for the phase I/II clinical trial CESTAFOUR

<< Newer press releases Older press releases >>

CEO interview, Redeye, (In Swedish) - 2021-08-31

Redeye

CEO interview, Di TV (In Swedish) - 2021-05-26

Di TV

CEO presentation AGM (In Swedish) - 2021-05-26

Bio Stock

CEO interview, Redeye, (In Swedish) - 2021-05-24

Redeye

CEO interview, Redeye, (In Swedish) - 2021-05-11

Redeye

Interview with CEO Göran Forsberg and CMO Ignacio Garcia-Ribas, Pareto - 2021-03-26

Pareto Securities

CEO interview, Edison - 2021-03-15

Edison

CEO interview, Redeye, (In Swedish) - 2021-03-09

Redeye

Cantargia in a panel discussion on how to build a successful biotech company (In Swedish) - 2021-01-27

Aktiespararna

CEO interview, Edison Open House - 2021-01-26

Edison

CEO interview, direct share issue, Redeye (In Swedish) - 2020-12-16

Redeye

CEO interview, direct share issue, Di TV (In Swedish) - 2020-12-16

Di TV

CEO interview, EFN (In Swedish) - 2020-10-16

EFN

CEO interview, Penser Bank Cancer Research Day (In Swedish) - 2020-10-07

Penser Bank

Article about Cantargias antibody based cancer treatment with multiple functions 2019-10-31

Affärstidningen Näringsliv

Presentation at ASCO 2019, follow up articles and interviews - 2019-07-02

ASCO

Cantargia interview at EFN after ASCO - 2019-06-17

EFN

CEO interview, Edison, London - 2019-02-26

Edison TV

CEO interview, EFN, Lund (In Swedish) - 2018-11-22

EFN

Interview around CAN04 clinical results, Redeye, Stockholm (In Swedish) - 2018-10-23

Redeye

Listing ceremony for Cantargia on Nasdaq Stockholm Main Market - 2018-09-25

Nasdaq

CEO interview in connection with listing Nasdaq Stockholm (Small Cap), EFN, Stockholm (In Swedish) - 2018-09-25

EFN

CEO interview in connection with listing Nasdaq Stockholm (Small Cap), Ditv, Stockholm (In Swedish) - 2018-09-25

Di

CEO interview, Redeye, Stockholm (In Swedish) 2018-09-06

Redeye

CEO interview, BioStock Live, Stockholm (In Swedish) -2018-08-29

Direkt Studios

Småbolagspanelen: Om framtidens cancerbehandlingar, Småbolagsdagen, Stockholm (in Swedish) 2018-06-11

Aktiespararna

CEO interview BioStock Live, Stockholm (In Swedish) -2018-03-20

Direkt Studios

CEO-interview 2017-12-12

Aktiespararna

Interview with Cantargia's CEO Göran Forsberg after the presentation at BioStock Live i Stockholm - 2017-12-04

Direkt Studios

CEO-interview - 2017-11-29

Finwire.tv

Video, interview Göran Forsberg, President Cantargia, Sedermera-dagen, Lund - 2016-03-16

Finwire.tv

© Copyright 2022 · Cantargia AB